Under Armour Ord Shs Class C (UA)
$8.37 0.27 (3.13%)
12:47 EDT UA Stock Quote Delayed 30 Minutes
Previous Close $8.64
Market Cap 1.88B
PE Ratio -49.24
Volume (Avg. Vol.) 2.21M
Day's Range 8.21 - 8.63
52-Week Range 6.37 - 24.55
Dividend & Yield N/A (N/A)
UA Stock Predictions, Articles, and Under Armour Ord Shs Class C News
- From InvestorPlace
- From the Web
Once a promising play on the athletic-wear market, UA stock has lost its luster and offers subpar prospects at this point.
As the broad market has bounced from March lows, UA stock has mostly been left out. It's not hard to see why: Under Armour's turnaround isn't working.
Under Armour's outlook is murky and UA stock looks expensive. The stock is likely to fall when Q2 and Q3 losses drag down the company's liquidity, book value and upside.
UAA stock received a boost on Friday after CEO Patrick Frisk said Under Armour's new sportsmasks sold out in less than an hour on Thursday.
Summer is kicking off and Americans are returning to the gym. Investors should look to strengthen their portfolios with these fitness stocks.
Under Armour (UAA) earnings for the athletic wear company's first quarter of 2020 have UAA stock taking a beating on Monday.
By Thomas Niel
Continued store closures due to coronavirus means more bad news for these five retail stocks. That said, sell them before shares head lower.
Following a steep loss from the coronavirus pandemic, Under Armour stock is finally showing positive momentum. However, this may be a bull trap as the underlying business has grown increasingly irrelevant.
With the pandemic pressuring the consumer retail market, UA stock has taken a dive. Still, that’s no excuse to buy shares as a toxic culture will stymie what is already a difficult recovery attempt.
The national stay-at-home orders are hitting the economy hard, and you should avoid these seven stocks to sell as a result of the quarantine.
Don't be fooled into seeing these stocks to sell as long-term buying opportunities. The good times just might be over for these companies.
Add in coronavirus headwinds, and what do you have? A stock that could fall further. Even after shares have taken a 50% haircut. 2020 guidance already implied tepid growth and earnings declines. "Social Distancing" could mean even worse performance in the coming year. Considering these factors, there's no reason to buy Under Armour stock. In short, sell shares now, before they fall further.
Under Armour stock plunged after Q4 earnings, but the declines aren't over. UAA stock remains expensive and a turnaround will take years.
Under Armour's sales woes continue as innovation is lacking -- keeping the pressure on UAA stock for the foreseeable future.
Under Armour earnings for the fourth quarter of 2019 have UA stock taking a beating on Tuesday.
Amazon, Under Armour, Facebook, FedEx and Hasbro were our top stock trades for Wednesday. That said, here's a look at the charts.
Thursday's big stock charts feature 3 names with big earnings reports ahead in a market whose attention likely has returned to fundamentals.
Fundamental improvements will push UAA stock higher in 2020, but the magnitude of those gains will be limited by valuation friction.
Growth stocks have led the decade-long market rally. Monday's 3 big stock charts feature 3 names that could be leaders in 2020 as well.
Nomura analyst Christopher Marai reiterated a Buy rating on Marker Therapeutics (NASDAQ: MRKR) on May 11 and set a price target of $16.00. The company’s shares closed last Tuesday at $2.09, close to its 52-week low of $1.33. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marker Therapeutics
In a research report published on 5/12, Janney Montgomery analyst Yun Zhong reiterated a Buy rating on Marker Therapeutics (NASDAQ:MRKR)with a price target of $10, which implies an upside of 378% from current levels. According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Yun Zhong has a
In a report issued on May 29, Anthony Butler from Roth Capital reiterated a Buy rating on Marker Therapeutics (NASDAQ: MRKR), with a price target of $6.00. The company’s shares closed last Tuesday at $2.09, close to its 52-week low of $1.33. Marker Therapeutics has an analyst consensus of Moderate Buy, with a price target
From Simply Wall St
Marker Therapeutics, Inc.’s (NASDAQ:MRKR): Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrkr/marker-therapeutics/news/when-will-marker-therapeutics-inc-nasdaqmrkr-become-profitable/">Read More...</a></div>
Oppenheimer analyst Matthew Biegler assigned a Buy rating to Marker Therapeutics (MRKR – Research Report) yesterday and set a price target of $10.00. The company’s shares closed last Monday at $2.16, close to its 52-week low of $1.33. According to TipRanks.com, Biegler is a 5-star analyst with an average return of 41.5% and a 78.9%
Navellier RatingsPowered by Portfolio Grader